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Abstract The chemokine receptor CCR5 is used as a major
coreceptor for fusion and entry by non-syncytia inducing
macrophage tropic isolates of HIV-1, which is mainly involved
in transmission. Individuals who are homozygous for the v32
allele of CCR5 are usually resistant to HIV-1 infection and
continue to lead a normal healthy life. Thus this gene is
dispensable and is, therefore, an attractive target in the host cell
for interfering specifically with the virus-host interaction. With
the aim to develop a specific antiviral approach at the molecular
level, we have synthesized a hammer-head ribozyme and a DNA-
enzyme. Both ribozyme and DNA-enzyme cleaved the CCR5
RNA in a sequence specific manner. This cleavage was protein
independent but Mg2 dependent. The extent of cleavage
increased with increasing concentration of magnesium chloride.
DNA-enzyme was more effective in cleaving a full length (1376
bases) in vitro generated transcript of CCR5 gene. In this
communication, we show that the DNA-enzyme when introduced
into a mammalian cell, results in decreased CD4-CCR5-gp160
mediated fusion of cell membranes. Potential applications of
these trans acting molecules are discussed.
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1. Introduction
HIV-1 requires cofactor molecules (chemokine receptors) in
addition to CD4 for entry and fusion into target cells (for
review [1^3]). These chemokine receptors are 7-transmem-
brane domain G-protein coupled receptors. Macrophage
tropic isolates (R5 viruses based on new classi¢cation) of
HIV-1 use CCR5 which is mainly responsible for person to
person transmission whereas T-lymphocyte tropic-syncytia in-
ducing isolates use CXCR-4 and appear late in the disease
([4,5] and above review articles). The CCR5 coreceptor is
used by primary HIV-1 isolates of almost all genetic subtypes,
HIV-2 [6] and SIV [7]. Nine other potential chemokine recep-
tors have been identi¢ed which can serve as a coreceptor for
either HIV or SIV (reviewed in reference [1]). Approximately
1% of the Caucasian population with European heritage is
homozygous for the v32 allele of CCR5 which a¡orded pro-
tection against HIV-1 infection despite multiple exposure [8^
11]. The protection is not absolute as three incidents of in-
fection have been reported recently [12^14]. This deletion cor-
responds to the second extracellular loop of the 7-transmem-
brane protein which results in frame shift mutation. A
severely truncated protein is expected which can neither act
as a coreceptor nor has the ability to transduce any signal [8].
Approximately 15^20% of people of European origin are het-
erozygous for the v32 allele of CCR5 [8^11]. They remain
fully susceptible to virus infection but the progression of the
disease is delayed [10]. Besides this deletion, many other types
of deletion have been reported but they are rare in occurrence
[15,16]. While this deleted allele was quite common among
European people, it was found remarkably absent among
Africans and Asians [8^11]. We recently reported the presence
of a normal individual who was heterozygous for v32 allele of
CCR5 gene from India [17] and studied the inheritance pat-
tern [18]. Since this gene is dispensable, it has become a target
for intervention by many groups. We have assembled a ham-
mer-head ribozyme and a DNA-enzyme for selective inactiva-
tion of this HIV-1 coreceptor as our antiviral approach. In
this communication, we demonstrate their in vitro cleavage
properties under variety of experimental conditions and
show the e¡ectiveness of the DNA-enzyme in speci¢c intra-
cellular down regulation of CCR5 gene in a functional assay
which is based on CD4 coreceptor gp160 mediated cell mem-
brane fusion.
2. Materials and methods
2.1. Plasmids used
We recently reported full length cloning of the CCR5 (wild-type as
well as v32 allele) gene from a heterozygous individual from India
[17,18]. The gene was placed under bacteriophage T7 promoter of the
plasmid pGEM-T-Easy (Promega Biotech., Madison, WI). For in
vivo studies, pCDNA-CCR5 plasmid was obtained from Marc Par-
mentier, Belgium. All the plasmids were puri¢ed on a Qiagen column
(Qiagen, Gmbh, Hilden, Germany) before sequencing or for the pur-
pose of transfection into mammalian cells.
2.2. Target site selection and construction of ribozyme
GUC (541 nt position of G residue) was selected for making the
hammer-head ribozyme. The following strategy was used to assemble
the ribozyme. A 38 nucleotides long oligonucleotide was synthesized
chemically. This was ampli¢ed by using two terminal primers and the
PCR ampli¢ed product was ligated into a T-tailed vector (pGEM-T-
Easy). The following primers were synthesized:
(1) Rz-541-5P-CAAGAGTTCTGATGAGTCCGTGAGGACGAAA-
CACATTG-3P. The sequence of the catalytic motif of the hammer-
head ribozyme is shown in bold letters and the sequence of 8 bases on
either side of this motif is also shown which provides speci¢city for
the target RNA (Fig. 1).
(2) Sense terminal primer 5P-CAAGAGTTCTGATGAG-3P.
(3) Antisense terminal primer 5P-CAATGTGTTTCGTCCTC.
The PCR conditions were the same as described before [17]. The
recombinant plasmids were checked for the ribozyme insert by diges-
tion with EcoRI. Recombinant clones were grown to large scale,
puri¢ed on a Qiagen column before subjecting them to sequencing
with forward sequencing and reverse sequencing primers provided in
the kit (Sequenase version 2, Amersham, Life Science). The ribozyme
FEBS 20897 5-10-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 1 3 7 - 5
*Corresponding author. Fax: +91 (11) 6162125.
E-mail: akhil@nii.ernet.in
FEBS 20897 FEBS Letters 436 (1998) 233^238
was found to be placed under SP6 promoter (Fig. 2). Therefore,
ribozyme transcripts were synthesized in vitro by using SP6 polymer-
ase.
2.3. In vitro transcription of substrate RNA and cleavage by ribozyme
and DNA-enzyme
Qiagen column puri¢ed plasmid pCCR5 DNA was linearized by
the restriction enzyme XbaI for full length transcripts of 1376 nt
and by BglII for 740 nt long transcripts respectively. The ribozyme
541 was linearized at a unique restriction site NcoI present in the MCS
(multiple cloning sites) of the vector pGEM-T-Easy. Transcription of
linearized plasmid DNAs were carried out using either T7 or SP6
polymerase (Promega Biotech) according to the directions of the man-
ufacturer and as described before [19]. RNAs were resolved on a 7 M
urea-7% polyacrylamide gel using the mini-protein gel system of
Biorad. Various steps involved from plasmid DNA to transcription
and cleavage by ribozymes and DNA-enzymes are shown in
Fig. 3.
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Fig. 1. Hammer-head ribozyme was assembled by standard recombi-
nant DNA methodology as described in the text and described be-
fore [29]. 541 nucleotide of the CCR5 gene [32] was targeted. PCR
ampli¢ed ribozyme DNA was cloned into pGEM-T-Easy (Promega
Biotech., Madison, WI) and con¢rmed by sequencing. A 22 nucleo-
tides hammer-head catalytic motif was placed between the target hy-
bridizing arms on either side of the C residue (which was left un-
paired) which were 8 bases long.
Fig. 2. The ribozyme DNA sequences were ampli¢ed by PCR as de-
scribed in the text and then cloned into pGEM-T-Easy. Clones har-
boring the ribozymes were grown to large scale in JM 109 cells and
the plasmid DNA was isolated according to standard procedures.
Before sequencing, the DNA was puri¢ed on a Qiagen column.
Both the strands were sequenced using forward and reverse sequenc-
ing primers provided in the sequencing kit (Sequenase version 2,
Amersham, Life Science). Note the presence of EcoRI site present
(in the polylinker region) on either side of the cloned ribozyme.
Fig. 3. Plasmid DNA encoding CCR5 gene was linearized by restriction enzymes (BglII and XbaI) to generate two classes of transcripts in
presence of labeled UTP using T7/SP6 RNA polymerase as described before [19]. After purifying the labeled transcripts, they were subjected to
cleavage by a ribozyme and a DNA-enzyme in presence of Mg2. The cleaved RNA fragment sizes have been shown. Once the cleavage oc-
curred, the ribozyme (Rz) or DNA-enzyme (Dz) are free to repeat the cycle on a new CCR5 RNA molecule. Diagram is not drawn to scale.
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2.4. Selection of target site for DNA-enzyme and cleavage conditions
AUG target site (position of A nucleotide being 916) was selected
as a target for DNA-enzyme that contained the recently identi¢ed 10^
23 catalytic motif [20]. Seven bases on either side of the A residue
(which was left unpaired and the cleavage is expected after the A
residue) was synthesized which was complementary to the target se-
quences (by Watson-Crick base pairing) and the catalytic motif was
placed in the middle of these hybridizing arms (Fig. 6). Equimolar
concentration of the substrate RNA (labeled) and cold DNA-enzyme
were added (100 picomoles) and the cleavage was initiated by adding
varying amounts of magnesium chloride by using the procedure fol-
lowed by Santoro and Joyce [20] and Kawabura et al. [21]. The
cleaved products were analyzed by gel electrophoresis as described
above.
2.5. Inhibition of cell membrane fusion by DNA-enzyme
The e¡ectiveness of the DNA-enzyme was assessed by a cell mem-
brane fusion assay as has been described by us recently wherein we
have tested the antisense e¡ect of a portion of CCR5 gene using
recombinant vaccinia virus [17]. Fusion dependent reporter gene (lu-
ciferase) activation assay as originally described by Nussbaum et al.
[22] was used. All the DNAs were used in 0.1 Wg quantity for trans-
fection into HeLa-CD4+ cells using lipofectin (GIBCO/BRL) includ-
ing the various control DNAs. Other ratios of CCR5 DNA and
DNA-enzymes were also used and they are explained in the ¢gure
legends. HeLa cells were used as control or they were made to express
CD4 by DNA transfection with the plasmid expressing it. The re-
combinant vaccinia virus was grown in HeLa cells and puri¢ed ac-
cording to the published procedures [23]. The infectivity of the virus
was determined by plaque assay using BSc-1 cells as described before
[24].
3. Results
3.1. Cloning of the CCR5 ribozyme 541
38 nucleotides long oligonucleotide which contained the 22
bases long earlier characterized hammer-head motif and 8
nucleotides on either side of the X residue from GUC target
which hybridizes with the target mRNA by Watson-Crick
base pairing was successfully cloned into pGEM-T-Easy.
The recombinant clones that contained the 38 bases pair insert
were grown to large scale and puri¢ed on a Qiagen column.
They were then subjected to sequencing using forward and
reverse sequencing primer provided by the manufacturer (Se-
quenase version 2, Amersham Life Science, Arlington
Heights, IL). The sequence of the ribozyme along with the
portion of multiple cloning site is shown in Fig. 2. The ribo-
zyme was cloned in 3P to 5P direction with respect to the T7
promoter which was £anked by the EcoRI restriction sites.
The 5P to 3P direction of the coding strand was exactly the
same as oligonucleotide #1 that was used as a template to
amplify using terminal primers. Thus, the ribozyme RNA
could be synthesized using SP6 promoter of the vector.
3.2. Sequence speci¢c cleavage of CCR5 (full length) RNA by
ribozyme
Plasmid DNA encoding CCR5 gene was linearized by BglII
and XbaI which after subjecting to in vitro transcription is
expected to generate a truncated (740 nt) or full length
CCR5 transcript of 1376 (Fig. 4A, lane 1) bases. The ribo-
zyme was tested for its ability to cleave these two classes of in
vitro generated substrate RNA molecules. The ribozyme spe-
ci¢c RNA was generated by linearizing the plasmid pGEM-
CCR5-Rz in the polylinker region of the vector using the
restriction enzyme NcoI. The size of the in vitro generated
ribozyme speci¢c transcript is 115 bases (lane 2). Lane 1
shows the synthesis of a full length labeled CCR5 RNA and
115 bases long labeled ribozyme transcript is shown in lane 2.
When equivalent amounts of cold ribozyme and labeled sub-
strates were added in equal amounts (100 picomoles each),
speci¢c 5P cleavage (540 bases) and 3P cleavage products
(836 bases) were observed (lanes 3 and 4). Cleavage reaction
was continued for 2 h at 37‡C in presence of 10 mM MgCl2.
In one case the substrate and ribozymes were heated to 90‡C
for 2 min before incubating at 37‡C (lane 3), in the other case
(lane 4) the entire cleavage reaction was performed at 37‡C.
Only about 5% speci¢c cleavage of the input substrate was
obtained when full length CCR5 RNA was used. Besides the
1376 bases long CCR5 transcript, there are two additional
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Fig. 4. A: XbaI digested CCR5 plasmid DNA when subjected to in
vitro transcription using the transcription kit from Promega Bio-
tech., yielded a transcript of 1376 bases (lane 1) and the plasmid
containing ribozyme (see text) generated a transcript of 115 bases in
presence of labeled UTP (lane 2). The cleavage reactions were car-
ried out with cold ribozyme and labeled CCR5 RNA (substrate).
Speci¢c cleavage products were seen in lanes 3 and 4 in the presence
of 10 mM MgCl2. The cleavage reaction was carried out for 2 h at
37‡C, in one case it was denatured at 90‡C for 2 min (lane 3) and
in the other case it was omitted (lane 4) before addition of magnesi-
um chloride. The cleaved RNA fragments were analyzed by gel elec-
trophoresis as described in the text. No cleavage was observed in
the absence of Mg2 (data not shown). B: The experimental details
of this experiment are the same as in the previous one (A). The
same ribozyme was used to cleave a truncated CCR5 RNA (740
bases long) which was generated by digesting the CCR5 plasmid by
BglII (see Fig. 3 and text). Lane 1 shows the synthesis of truncated
CCR5 RNA. Cleavage reaction was carried out for 2 h at 37‡C in
the presence of 2 mM MgCl2 (lane 2) and in the presence of 10 mM
MgCl2 (lane 3). When an additional heating step (90‡C for 2 min)
was introduced before initiating the cleavage reaction in presence of
2 mM MgCl2 (lane 4) and 10 mM MgCl2 (lane 5), increased cleav-
age was obtained. Note the increase in speci¢c cleavage at two dif-
ferent experimental conditions (compare lane 3 with lane 5). Cleav-
age at 10 mM MgCl2 was signi¢cantly better than 2 mM.
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minor RNA bands (lane 1), which were most likely because of
premature transcription which was seen earlier also with the
generation of in vitro transcription of other unrelated genes
[9]. Since the intensity of the cleaved RNA bands in lanes 3
and 4 increased with the time and not the premature tran-
scripts in lane 1, we conclude that they are produced as a
result of precise cleavage by ribozyme.
3.3. Cleavage of truncated CCR5 RNA (740 bases) by
CCR5-Rz-541
The experimental conditions for cleavage were essentially
the same except that instead of using a full length in vitro
generated CCR5 RNA, 740 bases long labeled CCR5 tran-
script was used. Lane 1 of Fig. 4B shows the synthesis of 740
bases long CCR5 transcript. Cleavage reactions were carried
out for 2 h at 37‡C (no prior heating step involved). Lanes 2
and 3 show the extent of speci¢c cleavage obtained in presence
of 2 and 10 mM MgCl2 concentrations respectively. Speci¢c
cleavage products (5P, 540 bases and 3P, 200 bases) could be
easily seen in lane 3 only. Lanes 4 and 5 show the extent of
cleavage obtained with 2 (lane 4) and 10 mM MgCl2 (lane 5)
when the labeled substrate RNA and ribozyme RNA were
heated at 90‡C for 2 min before addition of MgCl2. About
5% more cleavage was obtained if the mixture of ribozyme
and labeled substrate RNA (CCR5) was subjected to heat
treatment before addition of MgCl2 (compare lanes 3 and
5). We conclude from this that the same ribozyme worked
more e⁄ciently (V20% speci¢c cleavage) on a truncated
CCR5 RNA as compared to full length where the cleavage
was V5%.
3.4. E¡ect of the concentration of MgCl2 on cleavage e⁄ciency
The e¡ect of varying amounts of MgCl2 on the cleavage
e⁄ciency was studied using the 740 bases long in vitro gen-
erated labeled transcripts described earlier. Lane 1 shows the
presence of 740 bases long CCR5 (Fig. 5, lane 1) transcript in
presence of ribozyme which was not cleaved if the Mg2 was
omitted from the reaction. The extent of cleavage increased to
the extent of 85% in the presence of 100 mM MgCl2 (Fig. 5,
lane 6) (shown by arrows). Lanes 2, 3, 4 and 5 show the extent
of cleavage obtained in presence of 5, 10, 20 and 50 mM
MgCl2 respectively. We conclude that there is a direct corre-
lation of Mg2 with the cleavage e⁄ciency. It is remarkable
that the speci¢city of the ribozyme was not lost over a wide
range of concentration of MgCl2.
3.5. Target site selection for DNA-enzyme targeted against
CCR5 gene
AUG present in the coding region of CCR5 (position of A
being 916 nucleotide shown by a diagonal arrow) was chosen
for synthesizing a DNA-enzyme which possessed the earlier
identi¢ed 10^23 catalytic motif [20]. The sequence of the tar-
get gene and DNA-enzyme is shown in Fig. 6. The cleavage is
expected to take place after the A residue (shown by a long
arrow). Seven bases on either side of the A nucleotide are
made complementary to the target gene for hybridization by
Watson-Crick base pairing (Fig. 6). The catalytic motif [10^
23] possessing the sequence 5P-GGCTAGCTACAACGA-3P
was placed in between target hybridizing arms.
3.6. Targeted cleavage of full length CCR5 RNA by
DNA-enzyme 916
In vitro synthesized full length CCR5 (1376 bases) tran-
script was subjected to cleavage by equimolar amounts (100
picomoles) of DNA-enzyme and the cleavage reaction was
initiated by adding varying amounts of magnesium chloride
as described before [20,21]. Lane 1 of Fig. 7 shows the syn-
thesis of full length labeled CCR5 RNA, lanes 2 and 3 show
the cleavage obtained in presence of 2 and 10 mM MgCl2
when samples were denatured at 95‡C for 2 min followed
by 2 h at 37‡C. Lanes 4 (2 mM MgCl2) and 5 (10 mM MgCl2)
represent the same conditions except that the heating step was
omitted and the entire reaction was carried out at 37‡C. Al-
most 70% of the input substrate was cleaved into speci¢c
products of 916 and 460 bases long RNA fragments (lanes 3
FEBS 20897 5-10-98
Fig. 6. AUG sequence (position of A being 916) (shown by a diago-
nal arrow) was used to make the DNA-enzyme using the 10^23 cat-
alytic motif. Cleavage of the CCR5 RNA is expected to take place
after the A residue (shown by a long straight arrow). Seven bases
on either side of the unpaired A residue were synthesized chemically
which were complementary to the target sequence. The catalytic mo-
tif was placed between these two hybridizing arms (antisense
£anks).
Fig. 5. E¡ect of varying concentrations of MgCl2 on the cleavage
e⁄ciency of CCR5 ribozyme. The CCR5 transcript was 740 bases
long which was the same as described in Fig. 4B. Lane 1 shows the
presence of intact CCR5 RNA when the cleavage reaction was car-
ried out in the absence of MgCl2. The extent of cleavage increased
signi¢cantly as the concentration of MgCl2 was increased keeping
all other conditions identical, an almost complete cleavage of the
CCR5 RNA was achieved at 100 mM MgCl2 (lane 6). Lanes 2, 3,
4, and 5 show the extent of cleavage obtained at 5, 10, 20, and
50 mM MgCl2 respectively.
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and 5). Additional heating step did not improve the cleavage
e⁄ciency. We can not use the 740 bases long truncated CCR5
RNA for cleavage by this DNA-enzyme because this target
site is not present.
3.7. Inhibition of cell membrane fusion by DNA-enzyme
The detailed procedure for carrying out the gp160 (JRFL)-
CD4-CCR5 fusion based activation of a reporter gene assay is
based on the method described originally by Nussbaum et al.
[22] and also recently described by us [17,18]. Brie£y, the
DNA-enzyme and the CCR5 encoding DNA (varying ratios)
were cotransfected into HeLa cells that were expressing CD4
and fused with HeLa cells expressing HIV-1 Env protein and
T7 RNA polymerase. Fusion dependent reporter gene (luci-
ferase gene under T7 promoter) activation is measured. While
keeping the DNA constant (0.1 Wg each) for JRFL and CD4
plasmid, CCR5 DNA dose dependent increase in the cell
membrane fusion activity was observed (Table 1). When
DNA-enzyme was used in two di¡erent ratios (0.1 and 0.5
Wg), not only a dose dependent decrease (from 832 to 508
light units, Table 2) was seen but compared to an equivalent
amount of only CCR5 DNA (1655 light units (LU), Table 1),
it was signi¢cantly lower. Signi¢cant drop in the cell mem-
brane fusion activity was seen even when the plasmid DNA-
enzyme was ¢ve-fold lower (0.1 Wg) than CCR5 (0.5 Wg) (com-
pare 1832 LU in Table 1 with 985 LU in Table 2). From this,
we conclude that the DNA-enzyme in various combinations
of DNA-enzymes and CCR5 was able to interfere with the cell
membrane fusion. This was a speci¢c e¡ect as variety of con-
trol DNAs (pCDNA3, Promega Biotech., USA) as well as
control DNA-enzyme which was targeted against the X gene
of hepatitis B [25] virus failed to show this e¡ect (data not
shown). The sequence of this control DNA-enzyme (HBx-Dz-
307) was as follows: 5P-GTTGACAGGCTAGCTACAAC-
GATGCTGGGG-3P. The catalytic motif is the same as before
and expressed in bold letters. Also, the oligonucleotides that
lacked the catalytic motif but retained the 7+7 bases as anti-
sense £anks, failed to show this kind of e¡ect (data not
shown). This suggests that the observed e¡ect is most likely
mediated by the catalytic activity of the DNA-enzyme.
4. Discussion
With the purpose of selectively down regulating the repli-
cation of HIV, we have assembled a hammer-head ribozyme
and synthesized a DNA-enzyme which were targeted against
the chemokine receptor gene CCR5 (HIV coreceptor), which
is now considered essential for HIV-1 entry and fusion. The
hammer-head ribozyme was targeted against the 541 nucleo-
tide of the CCR5 gene by making use of the GUC sequence.
It is important to mention that most work on ribozymes or
DNA-enzymes use very short either synthetic or in vitro syn-
thesized RNA to test the cleavage potential [20,26,27]. This is
an arti¢cial situation and for this reason we have tested the
cleavage potential of our ribozyme (Rz) or DNA-enzyme (Dz)
on in vitro synthesized CCR5 RNA which was either full
length (1376 bases) or greater than 50% of its authentic size.
Precise cleavage of the substrate RNAs of both sizes were
obtained and as expected the cleavage was better with the
shorter substrate RNA. The size of the in vitro synthesized
ribozyme RNA using SP6 RNA polymerase is 115 bases from
the vector pGEM-T-Easy because of the sequences from the
multiple cloning site present between the SP6 promoter and
the region where we cloned our ribozyme gets transcribed.
The e⁄ciency of this ribozyme is likely to improve if a 38
bases long (the minimum size for a functional hammer-head
ribozyme) CCR5 ribozyme is placed directly under the SP6/T7
promoter. As expected, the e⁄ciency of cleavage with the
same ribozyme was better when the 740 bases long truncated
CCR5 transcript was used as compared to the full length. This
cleavage was greatly in£uenced by the concentration of MgCl2
and almost complete cleavage was obtained at 100 mM
MgCl2. Similar observations have been made for other unre-
lated ribozymes earlier [28]. A slight increase in the extent of
cleavage was observed with the addition of a denaturing step
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Table 2
Inhibition of cell membrane fusion by DNA-enzyme 916
Plasmid DNA used Luciferase activitya
JRFL+CD4+CR5 (0.1) +Dz (0.1) 832 þ 36
JRFL+CD4+CR5 (0.1) +Dz (0.5) 508 þ 29
JRFL+CD4+CR5 (0.5) +Dz (0.1) 985 þ 78
aAverage mean þ S.D. from two separate experiments. Dz is the ab-
breviated form for DNA-enzyme 916. The concentration for JRFL,
CD4 DNA was kept constant at 0.1 Wg for each experiment. Extent of
luciferase activity is a direct re£ection of the amount of membrane
fusion achieved, for details see text.
Table 1
CCR5-gp160-CD4 mediated cell membrane fusion
Plasmid DNAs used Luciferase activity
JRFL+CD4+CCR5 (0.01) 673 þ 59
JRFL+CD4+CCR5 (0.10) 1655 þ 93
JRFL+CD4+CCR5 (0.50) 1832 þ 98
CCR5 dependent increase in the cell membrane fusion activity. Values
represent average with standard deviation from two separate experi-
ments. For details see text.
Fig. 7. Sequence speci¢c cleavage of the full length in vitro gener-
ated CCR5 RNA (1376 bases) by DNA-enzyme 916. The reaction
conditions were the same as described before [20,21] and as de-
scribed in the text. Plasmid DNA-CCR5 was linearized by XbaI di-
gestion (see Fig. 3) and subjected to transcription as described be-
fore. Puri¢ed labeled transcript was then allowed to react with
DNA-enzyme (cold). Lane 1 shows the synthesis of CCR5 tran-
script. The cleavage reaction was continued for 2 h at 37‡C after a
2 min exposure at 95‡C for 2 min in presence of 2 mM MgCl2
(lane 2) or 10 mM MgCl2 (lane 3). In another set of experiments,
the samples were not subjected to 95‡C treatment but the entire re-
action was carried out at 37‡C in presence of 2 mM MgCl2 (lane 4)
and 10 mM MgCl2 (lane 5). Note the speci¢c cleavage products
being formed in lane 3 and lane 5. Cleavage at the higher concen-
tration of MgCl2 was signi¢cantly better than what was achieved at
2 mM MgCl2 concentration.
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before adding the MgCl2 for initiating the cleavage reaction.
This is most likely because of the melting of the secondary
structures which allows more e⁄cient hybridization. This
cleavage was Mg2 dependent and unrelated RNAs were
not cleaved by this ribozyme (data not shown). DNA-enzyme
that was targeted to cleave the 916th residue (A) of the CCR5
gene, also cleaved the full length CCR5 gene (1376 bases) into
speci¢c products and the extent of cleavage was more than
70% and an additional heating step prior to cleavage reaction
did not make any di¡erence (Fig. 7, compare lanes 3 and 5).
Although direct comparisons can not be made between the
ribozyme and the DNA-enzyme since they are targeted to
di¡erent regions of the CCR5 RNA (full length 1376 bases),
nevertheless, DNA-enzyme was found to be more e⁄cient. We
then addressed the question whether this DNA-enzyme could
act intracellularly in a functional assay described earlier. For
this, we ¢rst established that CCR5 DNA dependent increase
in cell membrane fusion was achieved (Table 1). We then used
a variety of ratios of CCR5 and the DNA-enzymes and found
in each case a signi¢cant drop in the membrane fusion activity
(compare Table 1 with Table 2). This decrease was speci¢c as
unrelated DNAs, HBx-Dz-370 (unrelated DNA-enzyme con-
trol targeted against the X gene of hepatitis B virus) or the
oligonucleotides devoid of the catalytic motif, failed to show a
signi¢cant reduction in cell membrane fusion (6 10%) (data
not shown). We conclude that DNA-enzyme was able to in-
terfere with the functional expression of this coreceptor. We
wish to subclone our ribozyme under a strong eukaryotic
promoter to ¢nd out its e¡ectiveness inside the cell. These
short RNA and DNA molecules can be explored for their
therapeutic ability to interfere with the replication of HIV.
It may be possible to make these ribozymes multitarget in
nature as has been reported against HIV-1 [29^31]. The
same approach could be applied to DNA-enzymes. Combina-
tions of these approaches along with other anti-retroviral
strategies may signi¢cantly delay the onset of the disease by
delaying the appearance of the resistant population of viruses.
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